Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 31 out of 100. Genetics

Topic: Amyloid, tau and blood-test diagnosis

Abstract Description The regional progression of brain atrophy in Alzheimer’s disease highly correlates with tau accumulation. There are changes in adaptive immunity in AD and the increases in activated CD8+ T cells in the brain correlate with tau pathology. Further, there is a dynamic transformation of the CD8+ T cell cellular characteristics from activated to exhausted states along with unique TCR clonal expansion. Depletion of brain-resident microglia, infiltrated T cells, as well as, inhibiting IFN-γ signaling all significantly ameliorated brain atrophy. To date, little is known about the interaction between T cells and brain resident microglia. Here we use APOE isoforms-dependent mouse models and human neuroimmune axis models to show that microglia coordinate immune modulatory response against immune challenges in AD. Adaptive immune deficiency had strongly decreased microglial reactivity and microglia-mediated synaptic engulfment in tauopathy. Adaptive Immune deficiency ameliorates Tau-linked glial lipid accumulation. Of note, using large-scale transcriptome and chromatin profiling, we show that T cell shape microglia-specific metabolic plasticity in both genetic and epigenetic resolution. Our results thus reveal a tauopathy and neurodegeneration-related immune hub involving activated microglia and T cell responses, which could potentially serve as therapeutic targets for preventing neurodegeneration in AD and primary tauopathies. Funding Sources This research was supported by Cure Alzheimer’s Foundation and Alzheimer’s Association Foundation. Topic Categories Neuroimmunology (NEUR)

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Chen, X. (2025). T cell drives microglia specific metabolic plasticity and neurodegeneration in Alzheimer disease 4098. The Journal of Immunology. https://doi.org/10.1093/jimmun/vkaf283.1823

Vancouver

Chen X. T cell drives microglia specific metabolic plasticity and neurodegeneration in Alzheimer disease 4098. The Journal of Immunology. 2025. doi:10.1093/jimmun/vkaf283.1823.

BibTeX

@article{chen2025-1d3c79ca,
  author  = {Chen, Xiaoying},
  title   = {{T cell drives microglia specific metabolic plasticity and neurodegeneration in Alzheimer disease 4098}},
  journal = {The Journal of Immunology},
  year    = {2025},
  doi     = {10.1093/jimmun/vkaf283.1823},
  url     = {https://doi.org/10.1093/jimmun/vkaf283.1823}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

Depletion of microglia, infiltrated T cells, or inhibition of IFN-γ signaling ameliorated brain atrophy in mouse models, revealing an immune hub involving activated microglia and T cell responses. These findings suggest potential therapeutic targets for preventing neurodegeneration in Alzheimer's disease and primary tauopathies.

Study details

How this study scored 31/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 4 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomised / blinded 0 of 2; Times cited 0 of 7; Citations per year 0 of 5; Impact for its field and year 0 of 6; Cited by studies here 0 of 6; Still being cited 0 of 4; Senior author's track record left out, no data; Institution's track record left out, no data; Multi-centre collaboration 0 of 3; Indexed in PubMed 1 of 2; Free to read 2 of 2. 29 of the 93 points it could be judged on, which is 31 of 100. Total 31 of 100.29 of the 93 points we could judge = 31 of 100

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it. We have no data on senior author's track record and institution's track record, so those were left out: it earned 29 of the 93 points we could judge it on, which is 31 out of 100.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (The Journal of Immunology)
Journal's citation record 4 / 4 The Journal of Immunology: journal h-index 531 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomised / blinded 0 / 2 No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 0 / 7 Cited 0 times (OpenAlex, 2026-10-10)
Citations per year 0 / 5 0.0 citations a year over 3 year(s) since 2025
Impact for its field and year 0 / 6 Cited 0.0× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 0 / 4 Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record — / 4 Senior author's record not available — left out of this score
Institution's track record — / 3 No institution listed in OpenAlex — left out of this score
Multi-centre collaboration 0 / 3 OpenAlex lists 0 institution(s) in 0 countries — scores zero (affiliation lists can be incomplete)
Indexed in PubMed 1 / 2 Not in PubMed, but has a DOI
Free to read 2 / 2 Free to read
Points 29 / 93 Scored on 18 of 20 parts. We have no data for the rest, so they are left out: 29 of the 93 points we could judge it on is 31 out of 100.
Total 31 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Related studies in Genetics

Also tagged “precursor”

1,339 studies in the library carry the topic tag “precursor”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,339 tagged studies.

Similar studies

More on Genetics

See all studies in Genetics →